首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >A Single-Center, Randomized Double-Blind Placebo-Controlled Study Evaluating the Effects of Poly-Gamma-Glutamate on Human NK Cell Activity after an 8-Week Oral Administration in Healthy Volunteers
【24h】

A Single-Center, Randomized Double-Blind Placebo-Controlled Study Evaluating the Effects of Poly-Gamma-Glutamate on Human NK Cell Activity after an 8-Week Oral Administration in Healthy Volunteers

机译:单中心,随机的双盲安慰剂对照研究评估多γ-谷氨酸在健康志愿者8周口服给药后对人NK细胞活性的影响

获取原文
获取原文并翻译 | 示例
       

摘要

A randomized double-blind placebo-controlled immunity study involving 99 healthy volunteers was performed to investigate the effect of poly-y-glutamate (y-PGA) on human natural killer (NK) cell activity in peripheral blood. The volunteers were randomly assigned to one of three groups and orally treated with solutions (25 mL) containing 0 mg (placebo), 250 mg (low dosage), or 500 mg (high dosage) of y-PGA. Each volunteer took one dose every 12 hours for 8 weeks. Blood samples' were drawn before the initial treatment and at the 4th and the 8th weeks of treatment. NK cell activity was assessed by measuring its degranulation, cytokine production, and cytotoxicity against the K562 cell line. Our results revealed that the cytotoxic activities of NK cells from the high-dosage y-PGA group were significantly higher (P < 0.05 for all comparisons) compared to the low dosage and placebo groups at weeks 4 and 8 after the initial treatment. This increase in the NK cell activity among peripheral blood mononuclear cells (PBMCs) of healthy individuals was also confirmed in vitro (as assessed by the degranulation and cytokine production). These results suggest that the oral administration of y-PGA induces a cell-mediated immunity by increasing the NK cell activity in humans.
机译:进行了涉及99个健康志愿者的随机双盲安慰剂控制的免疫研究,以研究聚-Y-谷氨酸(Y-PGA)对外周血中人类天然杀伤(NK)细胞活性的影响。将志愿者随机分配到三组中的三组中,并用含有0mg(安慰剂),250mg(低剂量)或Y-PGA的500mg(高剂量)的溶液(25ml)口服处理。每个志愿者每12小时服用一次剂量8周。在初始治疗之前和第4周和第8周之前绘制血液样本。通过测量其对K562细胞系的脱粒,细胞因子产生和细胞毒性来评估NK细胞活性。我们的研究结果表明,与在初始治疗后的第4周和第8周和第8周内的低剂量和安慰剂组相比,来自高剂量Y-PGA组的NK细胞来自高剂量Y-PGA组的细胞毒性活性显着更高(P <0.05)。在体外确认健康个体的外周血单核细胞(PBMC)的NK细胞活性增加(如通过脱粒和细胞因子产生的评估)。这些结果表明,Y-PGA的口服给药通过增加人体中的NK细胞活性来诱导细胞介导的免疫。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号